A carregar...
Publicação
Farmacoterapia da Colite Ulcerosa
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.6 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
As doenças inflamatórias intestinais, nomeadamente a doença de Crohn e a colite ulcerosa, são distúrbios digestivos caracterizados por uma inflamação crónica do trato gastrointestinal. Ambas as doenças apresentam sintomas semelhantes, sendo caracterizadas principalmente por diarreia crónica, com ou sem sangramento, dor abdominal e perda de peso. A sua incidência tem aumentado ao longo dos anos, sendo mais elevada na América do Norte, Europa e Oceânia. A prevalência é maior em indivíduos mais jovens, podendo variar de acordo com a localização geográfica, fatores genéticos, hábitos alimentares e resposta imunológica inadequada. A colite ulcerosa é uma doença inflamatória crónica cuja fisiopatologia envolve a inflamação da mucosa interna do colón, iniciando-se no reto e geralmente progride de forma contínua ao longo do intestino grosso. Pode ser classificada em duas formas, isto é, ligeira a moderada e moderada a severa. O sintoma mais característico da doença é a diarreia com presença de sangue. O seu diagnóstico baseia-se na interpretação geral das manifestações clínicas, aliada a exames laboratoriais, endoscópicos e histológicos. Durante a fase inicial, é essencial excluir causas infeciosas, particularmente a infeção por Clostridioides difficile. Tratando-se de uma doença crónica, o objetivo do tratamento é induzir uma resposta clínica rápida, normalizar os biomarcadores e manter a remissão clínica. A farmacoterapia depende da extensão e da fase da doença. Conforme a gravidade podem ser utilizados fármacos orais e tópicos, incluindo anti-inflamatórios intestinais (p. ex., messalazina), corticosteroides, tiopurinas e fármacos biológicos (p. ex., inibidores do fator de necrose tumoral do tipo alfa). A intervenção farmacêutica constitui um pilar fundamental em diferentes áreas, ao garantir a adesão terapêutica e a monitorização da efetividade e segurança da farmacoterapia, bem como a sua otimização de forma individualizada, contribuindo para uma gestão mais eficaz da patologia e centrada no doente.
Inflammatory bowel diseases (IBD), including Crohn´s disease and ulcerative colitis, are chronic disorders characterized by persistent inflammation of the gastrointestinal tract. Both conditions share similar symptoms, primarily chronic diarrhoea, with or without blood, abdominal pain, and weight loss. The incidence of IBD has increased over the years, with higher rates in North America, Europe, and Oceania. The prevalence is greater among younger individuals and can vary depending on geographic location, genetic factors, dietary habits, and immune system responses. Ulcerative colitis is a chronic inflammatory disease whose pathophysiology involves inflammation of the inner lining of the colon, starting in the rectum and typically progressing continuously through the large intestine. It’s generally classified as either mild to moderate or moderate to severe. The most characteristic symptom of the disease is diarrhoea with the presence of blood. Its diagnosis is based on the general interpretation of clinical manifestations, combined with laboratory, endoscopic and histological examinations. During the initial phase, it is essential to rule out infectious causes, particularly Clostridioides difficile infection. Because it is a chronic disease, the goal of treatment is to induce a rapid clinical response, normalize biomarkers, and maintain clinical remission. Pharmacotherapy depends on the extent and stage of the disease. Depending on the severity, oral and topical drugs may be used, including intestinal anti-inflammatory drugs (e.g., mesalazine), corticosteroids, thiopurines, and biologics (e.g., tumour necrosis factor-alpha inhibitors). Pharmaceutical intervention constitutes a fundamental pillar in different areas, by ensuring therapeutic adherence and monitoring the effectiveness and safety of pharmacotherapy, as well as its optimization on an individualized basis, contributing to a more effective and patient-centred management of the pathology.
Inflammatory bowel diseases (IBD), including Crohn´s disease and ulcerative colitis, are chronic disorders characterized by persistent inflammation of the gastrointestinal tract. Both conditions share similar symptoms, primarily chronic diarrhoea, with or without blood, abdominal pain, and weight loss. The incidence of IBD has increased over the years, with higher rates in North America, Europe, and Oceania. The prevalence is greater among younger individuals and can vary depending on geographic location, genetic factors, dietary habits, and immune system responses. Ulcerative colitis is a chronic inflammatory disease whose pathophysiology involves inflammation of the inner lining of the colon, starting in the rectum and typically progressing continuously through the large intestine. It’s generally classified as either mild to moderate or moderate to severe. The most characteristic symptom of the disease is diarrhoea with the presence of blood. Its diagnosis is based on the general interpretation of clinical manifestations, combined with laboratory, endoscopic and histological examinations. During the initial phase, it is essential to rule out infectious causes, particularly Clostridioides difficile infection. Because it is a chronic disease, the goal of treatment is to induce a rapid clinical response, normalize biomarkers, and maintain clinical remission. Pharmacotherapy depends on the extent and stage of the disease. Depending on the severity, oral and topical drugs may be used, including intestinal anti-inflammatory drugs (e.g., mesalazine), corticosteroids, thiopurines, and biologics (e.g., tumour necrosis factor-alpha inhibitors). Pharmaceutical intervention constitutes a fundamental pillar in different areas, by ensuring therapeutic adherence and monitoring the effectiveness and safety of pharmacotherapy, as well as its optimization on an individualized basis, contributing to a more effective and patient-centred management of the pathology.
Descrição
Palavras-chave
Doenças inflamatórias intestinais Colite ulcerosa Fisiopatologia Farmacoterapia Intervenção farmacêutica